165 results on '"KISH, JONATHAN"'
Search Results
2. Real-world observational study of current treatment patterns and outcomes in recurrent or locally advanced/metastatic non-small cell lung cancer
3. Harmonic Analysis on the Positive Rationals. Determination of the Group Generated by the Ratios $(an+b)/(An+B)$
4. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs
5. Harmonic Analysis on the Positive Rationals I: Basic Results
6. Harmonic Analysis on the Positive Rationals II: Multiplicative Functions and Maass Forms
7. Multiplicative Functions and a Taxonomy of Dirichlet Characters
8. A Large Sieve Inequality for Euler Products
9. Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer
10. Real-World Observational Study of Outcomes for Acute Myeloid Leukemia (AML) in Patients Treated with Glasdegib or Venetoclax in US Community Oncology Practices
11. Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLNFGFR1): A US Real-World Retrospective Cohort Study
12. Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicenter, US Real-World Study
13. Better Together? Costs of First-line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer.
14. Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer.
15. Economic and clinical impact of a novel, light-based, at-home antiviral treatment on mild-to-moderate COVID-19
16. Human-Associated Methicillin-Resistant Staphylococcus aureus from a Subtropical Recreational Marine Beach
17. Economic and clinical impact of a novel, light-based, at-home antiviral treatment on mild-to-moderate COVID-19
18. Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma
19. A generalization of Scholz's reciprocity law
20. Lower-Risk Myelodysplastic Syndromes: Erythropoiesis-Stimulating Agent Treatment Approaches and Outcomes in the United States
21. Clinical Outcomes at 3 and 6 Months of Fedratinib Therapy Following Prior Ruxolitinib Failure: Real-World Assessment of Spleen, Symptoms, and Hematologic Response
22. Real-World Utilization of Fedratinib for Myelofibrosis Post-Ruxolitinib: Patient Characteristics, Treatment Patterns, and Characterization of Ruxolitinib Failure
23. 562 Real-world assessment of current treatment patterns and clinical outcomes among patients with EGFR and ALK wild type non-small cell lung cancer (NSCLC) in the US
24. Real-World Investigation of Spleen, Symptom, and Hematologic Response in Patients with Myelofibrosis Treated with First-Line Ruxolitinib
25. Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials
26. Abstract PS13-37: Effectiveness of eribulin in poor prognosis subgroups of metastatic breast cancer (mBC) patients (elderly, African Americans, and patients with liver metastases) in the United States
27. 925 REDUCING REAL-WORLD HEALTHCARE RESOURCE UTILIZATION FOR PATIENTS WITH DIABETIC GASTROPARESIS (DGP) TREATED WITH METOCLOPRAMIDE NASAL SPRAY VERSUS ORAL METOCLOPRAMIDE
28. Physician treatment of metastatic triple-negative breast cancer in the immuno-oncology era: a discrete choice experiment
29. 731 Costs of care for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): a real-world claims analysis
30. Perceptions of community hematologists/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphoma
31. Comparative Effectiveness of Palliative Chemotherapy in Metastatic Breast Cancer: A Real‐World Evidence Analysis
32. The BEACHES Study: health effects and exposures from non-point source microbial contaminants in subtropical recreational marine waters
33. Real-World Incidence and Cost of Pneumonitis Post-Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer
34. Observational study of clinical outcomes of eribulin mesylate in metastatic breast cancer after cyclin-dependent kinase 4/6 inhibitor therapy
35. Neurological Adverse Events Following CAR-T Cell Therapy: A Real-World Analysis of Adult Patients Treated with Axicabtagene Ciloleucel or Tisagenlecleucel
36. Persistence of Ruxolitinib Treatment in Patients with Myelofibrosis at Community Oncology Practices in the United States-Contemporary Data
37. Real-World Utilization of Midostaurin Among Patients with Acute Myeloid Leukemia (AML)
38. Perceptions of Community Hematologists/Oncologists on Barriers to Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Diffuse Large B-Cell Lymphoma
39. Real-World Dosing Patterns of Ruxolitinib in Patients with Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea
40. Harmonic Analysis on the Positive Rationals II : Multiplicative Functions and Maass Forms
41. Harmonic Analysis on the Positive Rationals I : Basic Results
42. Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study
43. Real-world effectiveness of palonosetron-based antiemetic regimens: preventing chemotherapy-induced nausea and vomiting
44. Shedding of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus from adult and pediatric bathers in marine waters
45. Cost-Effectiveness Comparison between Ibrutinib, Chemotherapy, and Chemoimmunotherapy in Front-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
46. Comparison of Costs and Health Care Resource Utilization (HRU) in Chronic Lymphocytic Leukemia (CLL) Patients Treated with Venetoclax (VEN) or Chemotherapy (CT)/Chemoimmunotherapy (CIT)
47. Real-World Risk Assessment and Treatment of Patients with Myelofibrosis at Community Oncology Practices in the United States
48. Real-world incidence and cost of pneumonitis post-chemoradiotherapy for Stage III non-small-cell lung cancer.
49. Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting
50. Prioritizing US Cervical Cancer Prevention With Results From a Geospatial Model
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.